These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 28151746)

  • 21. Differences in target estimands between different propensity score-based weights.
    Austin PC
    Pharmacoepidemiol Drug Saf; 2023 Oct; 32(10):1103-1112. PubMed ID: 37208837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Should a propensity score model be super? The utility of ensemble procedures for causal adjustment.
    Alam S; Moodie EEM; Stephens DA
    Stat Med; 2019 Apr; 38(9):1690-1702. PubMed ID: 30586681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies.
    Austin PC
    Stat Med; 2010 Sep; 29(20):2137-48. PubMed ID: 20108233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of two propensity score-based methods for balancing covariates: the overlap weighting and fine stratification methods in real-world claims data.
    Wan W; Murugesan M; Nocon RS; Bolton J; Konetzka RT; Chin MH; Huang ES
    BMC Med Res Methodol; 2024 Jun; 24(1):122. PubMed ID: 38831393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Propensity-score-based Fine Stratification Approach for Confounding Adjustment When Exposure Is Infrequent.
    Desai RJ; Rothman KJ; Bateman BT; Hernandez-Diaz S; Huybrechts KF
    Epidemiology; 2017 Mar; 28(2):249-257. PubMed ID: 27922533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An evaluation of inverse probability weighting using the propensity score for baseline covariate adjustment in smaller population randomised controlled trials with a continuous outcome.
    Raad H; Cornelius V; Chan S; Williamson E; Cro S
    BMC Med Res Methodol; 2020 Mar; 20(1):70. PubMed ID: 32293286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methods for estimating subgroup effects in cost-effectiveness analyses that use observational data.
    Kreif N; Grieve R; Radice R; Sadique Z; Ramsahai R; Sekhon JS
    Med Decis Making; 2012; 32(6):750-63. PubMed ID: 22691446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Addressing Extreme Propensity Scores via the Overlap Weights.
    Li F; Thomas LE; Li F
    Am J Epidemiol; 2019 Jan; 188(1):250-257. PubMed ID: 30189042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. One-to-many propensity score matching in cohort studies.
    Rassen JA; Shelat AA; Myers J; Glynn RJ; Rothman KJ; Schneeweiss S
    Pharmacoepidemiol Drug Saf; 2012 May; 21 Suppl 2():69-80. PubMed ID: 22552982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variance estimation of the risk difference when using propensity-score matching and weighting with time-to-event outcomes.
    Cafri G; Austin PC
    Pharm Stat; 2023; 22(5):880-902. PubMed ID: 37258420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimating the effect of treatment on binary outcomes using full matching on the propensity score.
    Austin PC; Stuart EA
    Stat Methods Med Res; 2017 Dec; 26(6):2505-2525. PubMed ID: 26329750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Propensity score trimming mitigates bias due to covariate measurement error in inverse probability of treatment weighted analyses: A plasmode simulation.
    Conover MM; Rothman KJ; Stürmer T; Ellis AR; Poole C; Jonsson Funk M
    Stat Med; 2021 Apr; 40(9):2101-2112. PubMed ID: 33622016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Performance of the High-dimensional Propensity Score in a Nordic Healthcare Model.
    Hallas J; Pottegård A
    Basic Clin Pharmacol Toxicol; 2017 Mar; 120(3):312-317. PubMed ID: 27889951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.
    Hippisley-Cox J; Coupland C; Logan R
    BMJ; 2005 Dec; 331(7528):1310-6. PubMed ID: 16322018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two-stage matching-adjusted indirect comparison.
    Remiro-Azócar A
    BMC Med Res Methodol; 2022 Aug; 22(1):217. PubMed ID: 35941551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of propensity scores, disease risk scores, and regression in confounder adjustment for the safety of emerging treatment with group sequential monitoring.
    Xu S; Shetterly S; Cook AJ; Raebel MA; Goonesekera S; Shoaibi A; Roy J; Fireman B
    Pharmacoepidemiol Drug Saf; 2016 Apr; 25(4):453-61. PubMed ID: 26875591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pain management today - optimising the benefit/risk ratio: defining the role of weak opioids and combination analgesics.
    Schnitzer TJ
    Clin Rheumatol; 2006; 25 Suppl 1():S1. PubMed ID: 16741782
    [No Abstract]   [Full Text] [Related]  

  • 38. Propensity score matching and complex surveys.
    Austin PC; Jembere N; Chiu M
    Stat Methods Med Res; 2018 Apr; 27(4):1240-1257. PubMed ID: 27460539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Addressing substantial covariate imbalance with propensity score stratification and balancing weights: connections and recommendations.
    Thomas LE; Thomas SM; Li F; Matsouaka RA
    Epidemiol Methods; 2023 Jan; 12(1):20220131. PubMed ID: 38013684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The performance of different propensity score methods for estimating marginal odds ratios.
    Austin PC
    Stat Med; 2007 Jul; 26(16):3078-94. PubMed ID: 17187347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.